Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This study constructed a consensus single-cell atlas for hidradenitis suppurativa tunnels, identifying distinct fibro-inflammatory microenvironments with potential drug targets, suggesting TNF blockade alone may not be effective for all lesion types.

This study's new single-cell atlas of hidradenitis suppurativa tunnels identifies distinct fibro-inflammatory microenvironments, suggesting that TNF blockade may not address the primary pathway in many lesions.

This study created a comprehensive single-cell atlas of hidradenitis suppurativa tunnels, identifying distinct microenvironmental endotypes linked to specific signaling pathways, suggesting that TNF blockade may not effectively address predominant pathways in many lesions and highlighting the potential for individualized treatment strategies.

This study constructed a consensus single-cell atlas of hidradenitis suppurativa tunnels, identifying distinct microenvironmental endotypes with different inflammatory and fibrotic profiles, suggesting that TNF blockade may not be sufficient for addressing all lesions.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

This review discusses how urban air pollutants may influence the regulation of JAK3 signaling in alopecia areata and reports no new experimental results; the authors integrate existing data to map potential pathways and biomarkers.

This study found that cell-free RNA, particularly DNAJB9, shows potential as a biomarker for diagnosing and prognosing female androgenetic alopecia using a machine learning model.

This study examines the genetic underpinnings of chronic dermatological conditions like acne, androgenetic alopecia, and alopecia areata, concluding that a deep understanding of these mechanisms can advance patient-specific treatments and inform cosmetic practices related to skin and hair health.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This review discusses the mechanisms underlying the collapse of hair follicle immune privilege in alopecia areata and emphasizes the importance of therapeutic strategies aimed at restoring immune tolerance.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

This review explores emerging therapies for hair regrowth, highlighting two strategies: hair follicle neogenesis and Wnt/B-catenin pathway modulation, which show promise for treating alopecia by potentially offering more effective options than existing treatments.

This review discusses central centrifugal cicatricial alopecia in adult women of African descent and reports no clinical results; the authors highlight traditional treatments and their impact on quality of life.

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

This study found that in a human skin organ culture model of pemphigus vulgaris, split formation led to significant upregulation of IFNγ and TNFα-related genes, indicating secondary effects from mechanical stress, not direct changes from autoantibodies.

In this case report, researchers described a rare instance of granuloma annulare in a six-year-old child mimicking alopecia mucinosa, highlighting the importance of clinicopathologic correlation in diagnosing dermatological conditions. Treatment with topical mometasone furoate led to a satisfactory improvement and complete resolution within seven months.

In this study of Zhexi Angora rabbits, researchers found that the fine-wool group exhibited lower fiber diameters and a higher hair follicle density than the coarse-wool group, and they identified key candidate genes potentially regulating wool quality through RNA-seq and genome resequencing techniques.